论文部分内容阅读
目的观察莫沙必利联合复方消化酶胶囊治疗功能性消化不良的临床疗效和安全性。方法 2008年1月-2009年7月对62例功能性消化不良患者随机分为两组,每组31例,两组均口服莫沙必利片,三餐饭前30min服用5mg;试验组加服复方消化酶胶囊,进餐后30min服用1粒。4周后观察疗效。结果试验组治疗总有效率明显优于对照组,分别为87.1%和61.3%(P<0.05)。对上腹痛、餐后饱胀、早饱、上腹烧灼感症状改善情况进行比较,试验组治疗前后的症状总积分及症状改善有效率与对照组比较差异有统计学意义(P<0.05),而且起效时间明显缩短。两组患者均未发现严重不良反应。结论莫沙必利联合复方消化酶胶囊治疗功能性消化不良安全有效,其疗效明显优于单用促动力药莫沙必利。
Objective To observe the clinical efficacy and safety of mosapride combined with compound digestive enzyme capsule in the treatment of functional dyspepsia. Methods From January 2008 to July 2009, 62 patients with functional dyspepsia were randomly divided into two groups (31 in each group). Mosapride tablets were orally taken in both groups and 5 mg for 30 min before meals. The experimental group Services compound digestive enzymes capsules, taking a meal after 30min. After 4 weeks to observe the effect. Results The total effective rate of the experimental group was significantly better than that of the control group (87.1% vs 61.3%, P <0.05). The symptoms of upper abdominal pain, postprandial fullness, early satiety and upper abdominal burning sensation were compared. The total symptom score and symptom improvement rate before and after treatment in the experimental group were significantly different from those in the control group (P <0.05) And the onset time was significantly shorter. No serious adverse reactions were found in both groups. Conclusion Mosapride combined with compound digestive enzyme capsules is safe and effective in treating functional dyspepsia, and its efficacy is obviously superior to mosapride alone.